TP53 and neoplasm: Even in the 2023 renewed International Federation of Gynecology and Obstetrics (FIGO) staging system for EC molecular, properties like abnormal p53 expression or polymerase epsilon exonuclease domain mutation (POLE-EDM) are directly affecting tumor stage (1–3).